Skip to content

Effectiveness of a Combined Strategy to Improve Therapeutic Compliance and Degree of Control Among Patients With Hypercholesterolaemia

Effectiveness of a Combined Strategy to Improve Therapeutic Compliance and Degree of Control Among Patients With Hypercholesterolaemia: a Randomised Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02314663
Acronym
EFESCOM
Enrollment
358
Registered
2014-12-11
Start date
2013-01-31
Completion date
2015-12-31
Last updated
2014-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia, Medication Adherence, Primary Health Care

Keywords

hypercholesterolaemia, medication adherence, primary health care

Brief summary

Background In subjects with hypercholesterolaemia, cholesterol values remain above guideline levels. One of the limiting factors to the achievement of goals in such patients is therapeutic non-adherence. The aim of this study is to assess the effectiveness of an intervention designed to improve control of hypercholesterolaemic patients, consisting of a combined strategy that would include the delivery of printed information, treatment-compliance check cards and the dispatch of text messages as complementary measures in support of the intervention at the general practitioner's practice. Methods/Design A randomised, parallel-group clinical trial will be conducted at the family medicine outpatient facilities of eight health centres in three of Spain's Autonomous Regions, covering a total of 358 subjects aged 18 years or over with diagnosis of hypercholesterolaemia. Patients in the intervention group will be supplied with printed material with information on the disease and its management, mobile-telephone text messages with guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance, and self-report cards to check compliance with recommendations. Both groups -intervention and control- will receive routine recommendations from their physicians in accordance with current European clinical practice guidelines for hypercholesterolaemia and cardiovascular risk management. As regards the measurements to be made, the main variable is the proportion of subjects who attain the low density lipoprotein cholesterol levels set as a target across a follow-up period of 24 months. The secondary variables are as follows: adherence to recommendations on lifestyle and adherence to drug treatment; variation in lipid profiles and cardiovascular risk levels; appearance of cardiovascular events; physical activity; food consumption; smoking habit; anthropometric measures; blood pressure; health problems; use of hypolipidaemic agents; socio-demographic data; beliefs and expectations about preventive recommendations; and degree of satisfaction with the combined strategy. Discussion Should this intervention prove effective, a recommendation could be issued on the application of this combined strategy to subjects with hypercholesterolaemia. It is a simple, relatively inexpensive intervention.

Interventions

Participants in the intervention group will be supplied with: a) printed matter containing information on the disease and its management (this will be handed out at each of the follow-up visits); b) mobile-telephone text messages containing guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance (in the periods between visits); and, c) self-report cards to check compliance with recommendations (across the entire follow-up).

Sponsors

Instituto de Salud Carlos III
CollaboratorOTHER_GOV
Gerencia de Atención Primaria, Albacete
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* be diagnosed with hypercholesterolaemia, as defined according to the criteria stipulated in the cardiovascular prevention guidelines of the 2009 Prevention Activities and Promotion of Health Programme (total cholesterol of 250 mg/dl or higher). * be patients aged 18 years or over attending any of the participating health centres.

Exclusion criteria

* any person hindered from participating in the follow-up of the proposed intervention, e.g., illiterate subjects and non-users of mobile telephones. * any person with a physical disability or impairment which prevents him/her from attending the follow-up visits. * any person suffering from a significant chronic organic or psychiatric disease.

Design outcomes

Primary

MeasureTime frameDescription
The proportion of subjects who attain the LDL-C levels set as targets by the Guidelines for Management of Dyslipidaemias and CVR24 monthsThe main study variable is the proportion of subjects who attain the LDL-C levels set as targets by the Guidelines for Management of Dyslipidaemias and CVR, across a follow-up period of 24 months. The plasma values taken as cardiovascular prevention targets are: a) LDL-C \<100 mg/dl for patients without established cardiovascular disease or diabetes mellitus; and, b) LDL-C \<70 mg/dl for patients with diabetes mellitus or established cardiovascular disease

Secondary

MeasureTime frameDescription
variation in plasma lipid profile levels24 monthsvariation in plasma lipid profile levels (total cholesterol, LDL-C, HDL-C and triglycerides
variation in cardiovascular risk level24 monthsSCORE and REGICOR tables will be used for the evaluation
Occurrence of cardiovascular events24 monthsIschaemic heart disease, atherothrombotic cerebrovascular disease, heart failure and peripheral artery disease
determination of the frequency of food consumption24 monthsdetermination of the frequency of food consumption
smoking habit (answers affirmatively to the question, Do you smoke?)24 monthssmoking habit, with a smoker being defined as anyone who answers affirmatively to the question, Do you smoke?
adherence to lifestyle guidelines and adherence to drug treatment24 monthsadherence to lifestyle guidelines and adherence to drug treatment, as seen from self-reported adherence (adapted Haynes-Sackett test), validated questionnaire (Morisky-Green test) and Likert scale with 5 response options
anthropometric measures (i.e., weight, height, body mass index (BMI), and waist circumference)24 monthsi.e., weight, height, body mass index (BMI), and waist circumference
systolic and diastolic blood pressure24 monthssystolic and diastolic blood pressure (two measurements), with the result being the mean of the two results
degree of satisfaction with the combined strategy ((Likert scale with 5 response options ranging from 1 very dissatisfied to 5 very satisfied)24 monthsdegree of satisfaction with the combined strategy according to a satisfaction questionnaire (Likert scale with 5 response options ranging from 1 very dissatisfied to 5 very satisfied).
health problems (WONCA ICPC-2 classification)24 monthshealth problems
use of hypolipidaemic drug treatment24 monthsuse of hypolipidaemic drug treatment (type of drug and dose)
physical activity (degree of aerobic physical exercise performed (active, partially active or inactive)24 monthsphysical activity, i.e., determination of the degree of aerobic physical exercise performed (active, partially active or inactive)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026